Related Experiment Video

Updated: Oct 5, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.6K

Skeletal muscle metastases: pitfalls and challenges of a highly inhospitable environment

Angioletta Lasagna1, Matteo Ghiara2, Antonio A Mahagna2

  • 1Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Piazzale C. Golgi 19, Pavia 27100, Italy.

Future Oncology (London, England)
|January 31, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
angiogenesisantimetastatic nichelactic acidmuscle metastasestumor microenvironment

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K
Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

10.1K

Related Experiment Videos

Last Updated: Oct 5, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K
Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

10.1K

Related Concept Videos

Metastasis02:30

Metastasis

5.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.8K

Articles linked to this work by shared authors, journal, and citation graph.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

European journal of cancer (Oxford, England : 1990)·2026

Glioblastoma MRI Dataset with Standardized Preprocessing, Expert-Validated Segmentation, and MGMT Profiling.

Scientific data·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.

European urology open science·2026

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

The New England journal of medicine·2026

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

Clinical genitourinary cancer·2026

Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma.

Future oncology (London, England)·2026

Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.

Future oncology (London, England)·2026

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.

Future oncology (London, England)·2026

Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.

Future oncology (London, England)·2026

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

Future oncology (London, England)·2026

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

Future oncology (London, England)·2026

Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation.

Investigative ophthalmology & visual science·2026

Gut microbiota-derived metabolites and host interactions in fibrotic diseases: mechanisms, cross-organ signatures, and therapeutic opportunities.

Frontiers in microbiology·2026

Direct comparison of serine restriction on the viability of normal and cancer cells demonstrates that methionine restriction is more cancer specific.

Frontiers in oncology·2026

Mitophagy as an active regulator of cardiac metabolic reprogramming.

Frontiers in cardiovascular medicine·2026

Regulatory mechanisms and interactions of mitophagy and ketone body metabolism in cardiac metabolism.

Frontiers in cardiovascular medicine·2026

The Methionine-Mitochondria Axis in Cancer: Metabolic Cross-Talk and Therapeutic Vulnerabilities.

Current pharmacology reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us